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Pain is a multidimensional experience and negative affect, or how much the pain is “bothersome”, significantly impacts the sufferers’
quality of life. It is well established that the  opioid system contributes to depressive and dysphoric states, but whether this system
contributes to the negative affect precipitated by the occurrence of chronic pain remains tenuous. Using a model of persistent pain, we
show by quantitative real-time-PCR, florescence in situ hybridization, Western blotting and GTPgS autoradiography an upregulation of
expression and the function of  opioid receptors (KORs) and its endogenous ligand dynorphin in the mesolimbic circuitry in animals
with chronic pain compared with surgical controls. Using in vivomicrodialysis and microinjection of drugs into the mesolimbic dopa-
mine system, we demonstrate that inhibiting KORs reinstates evoked dopamine release and reward-related behaviors in chronic pain
animals. Chronic pain enhanced KOR agonist-induced place aversion in a sex-dependent manner. Using various place preference para-
digms, we show that activation of KORs drives pain aversive states inmale but not femalemice. However, KOR antagonist treatment was
effective in alleviating anxiogenic anddepressive affective-likebehaviors inboth sexes. Finally, ablationofKORs fromdopamineneurons
using AAV-TH-cre in KORloxP mice prevented pain-induced aversive states as measured by place aversion assays. Our results strongly
support the use of KOR antagonists as therapeutic adjuvants to alleviate the emotional, tonic-aversive component of chronic pain, which
is argued to be the most significant component of the pain experience that impacts patients’ quality of life.
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Introduction
Systems involved in pain processing interact extensively with
other affective and motivational systems (Elman et al., 2013).
This is most evident in the epidemiological evidence that shows
that chronic pain is second only to bipolar disorder as a major
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Significance Statement
We show that KORs are sufficient to drive the tonic-aversive component of chronic pain; the emotional component of pain that is
argued to significantly impact a patient’s quality of life. The impact of our study is broadly relevant to affective disorders associ-
atedwith disruption of reward circuitry and thus likely contributes tomany of the devastating sequelae of chronic pain, including
the poor response to treatment of many patients, debilitating affective disorders (other disorders including anxiety and depres-
sion that demonstrate high comorbidity with chronic pain) and substance abuse. Indeed, coexisting psychopathology increases
pain intensity, pain-related disability and effectiveness of treatments (Jamison and Edwards, 2013).
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cause of suicide among all medical illnesses (Asmundson and
Katz, 2009; Elman et al., 2013). Risk factors for suicide in chronic
pain patients include pain severity, pain type, catastrophizing,
poor sleep, perception of disability, presence of comorbid depres-
sion, and access to analgesics (Hassett et al., 2014). Mood disor-
ders are highly comorbid in chronic pain patients, where the
prevalence of depression ranges between 30 and 80%, depending
on the pain etiology (Bair et al., 2003; Howe and Sullivan, 2014).
It is consistently reported that chronic pain patients with comor-
bid psychopathology exhibit increased pain intensity and in-
creased pain-related disability (Jamison and Edwards, 2013;
Martel et al., 2014). For example, intravenous morphine is 40%
more effective in chronic pain patients without coexisting psy-
chopathology (Jamison and Edwards, 2013).
The Analgesic, Anesthetic, and Addiction Clinical Trial
Translations Innovations Opportunities and Networks public–
private partnershipwith theU.S. Food andDrugAdministration,
and theAmerican Pain Society have joined together to develop an
evidence-based chronic pain classification system termed the
ACTTION-APS Pain Taxonomy (Fillingim et al., 2014). Part of
this taxonomy recognizes the multidimensional and biopsycho-
social nature of chronic pain, which is subject to comorbidities
that impact the experience of chronic pain. It was argued that the
reliance on reflex behavioral outcomes in animal pain models
that measure changes in sensory nociceptive thresholds (me-
chanical, thermal, chemical) has led to poor predictive transla-
tional outcomes. As such, the myriad of promising candidate
analgesics identified by preclinical pain studies relying on these
sensory outcomes have failed in clinical trials (Mogil and Crager,
2004; Cobos and Portillo-Salido, 2013; Percie du Sert and Rice,
2014; Yaksh et al., 2015). Thus, capturing ongoing pain and neg-
ative affective in chronic pain models are necessary for future
analgesic drug development. This is emphasized by research find-
ings that show that negative affect not only exacerbates the pain
experience, it also is a predictor of opioid prescription misuse
leading to an opioid use disorders (Evans and Cahill, 2016).
Activation of  opioid receptors (KORs) produces negative
affect. For example, KOR agonists produce dysphoric effects and
elicit psychotomimetic properties in humans, as well as elicit
place aversion and depressive-like affective behaviors in rodents
(Shippenberg et al., 1993; Knoll andCarlezon, 2010; Chavkin and
Koob, 2016). Indeed, KOR agonists produce signs of anxiety,
fear, and depression in animals and humans (Chartoff and Ma-
vrikaki, 2015). One mechanism implicated in -mediated aver-
sion is the modulation of mesolimbic dopamine circuitry, where
KORs are expressed on dopamine terminals. Activation of KORs
following systemic agonist treatment reduces dopamine release
(Chefer et al., 2013). Ablation of KORs from dopamine neurons
(Van’t Veer and Carlezon, 2013) or KORs on BLA glutamatergic
neurons that project to the medial PFC (Tejeda et al., 2015) re-
sults in an anxiolytic phenotype, suggesting that these circuits are
critical to the expression of negative affective-like behavior.
Others, and we identified that mesolimbic circuitry dysfunction,
including that occurring in dopamine neurotransmission, pre-
cipitates mood disorders, impairs motivated behavior, and likely
contributes to chronic pain (Taylor, 2013; Cahill et al., 2014a,b;
Yalcin and Barrot, 2014; Taylor et al., 2016; Cahill and Taylor,
2017).
Considering that the circuitry involved in pain processing and
affective/motivational systems overlaps extensively, we investi-
gated specifically whether KOR contributes to the aversive nature
of chronic pain. In a rodent model of chronic neuropathic pain,
we show that the endogenous tone of the KOR system within
mesolimbic dopaminergic circuitry is robustly increased. Impor-
tantly, we show that KOR blockade or elimination of KOR in
midbrain dopamine neurons alleviates a tonic-aversive compo-
nent of chronic neuropathic and inflammatory pain, which is
sex-dependent. However, attenuation of depressive and anx-
iogenic affective-like behaviors by KOR antagonism is not sex-
dependent, suggesting a dichotomy of mechanisms between
affective dimensions of chronic pain and the ongoing tonic-
aversive states.
Materials andMethods
Animals.Male and female C57BL/6J wild-type (WT)mice were obtained
(Jackson Laboratories) at 8 weeks of age. Male Long–Evans rats (250–300
g) were obtained from Charles River Laboratories. Mice acing one func-
tional copy of the pre-proenekephalin (PENK ) gene (Ko¨nig et al., 1996;
C57BL/6 background) were bred to generate PENK knock-out (KO)
mice and WT littermates. The PENK KO and control mice were used
beginning at 9–10 weeks of age. KOR conditional KOmice (Ehrich et al.,
2015) were obtained from JAX laboratories at 9–10 weeks of age. This
latter transgenic mouse strain was on a mixed 129/C57 background.
Mice were housed in groups of two to four per cage on a 12 h reverse
light/dark cycle with food and water available ad libitum. Long–Evans
rats (250–300 g) were housed in pairs on a 12 h reverse light/dark cycle
with food and water available ad libitum. Rodents were allowed to habit-
uate to their housing environments for 1 week before handling. Experi-
mentswere conducted in the dark phase between 9:00 and 16:00 h. To the
extent possible, experimenters handling mice were blind to surgery, ge-
notype, sex, and drug treatment. Importantly, all tests were performed by
experimenters’ blind to experimental condition. Mice were assigned to
experimental conditions in a randomized block design so that factors
such as time of day were counterbalanced over the experimental condi-
tions. For experiments that had large numbers of groups, we completed
experiments using successive cohorts ensuring that experiments were
performed for all conditions within each cohort. All replications were
balanced with respect to experimental groups. All procedures were pre-
approved by the University of California, Irvine Institutional Animal
Care and Use Committee, the University of California, Los Angeles
Chancellor’s Animal Research Council, or the Canadian Council on An-
imal Care and the Queen’s University or University of Calgary Animal
Care Committees.
Drugs. The U50,488, U69,593, and naloxone were obtained from
Sigma-Aldrich and dissolved in 0.9% sterile saline. The JDTic, a highly
specific, long-acting KOR antagonist (Deehan et al., 2012; Munro et al.,
2012; Wu et al., 2012; Chavkin and Martinez, 2015) was obtained from
Dr. F. Ivy Carroll (Research Triangle Institute International) and dis-
solved in 0.9% sterile saline. The AAV-TH-cre and AAV-GFP were ob-
tained from Dr. Caroline Bass at the University of Buffalo (Gompf et al.,
2015).
Peripheral nerve injury neuropathic pain model. Mice and rats were
randomly assigned into either [pain]-naive (no surgery but exposed to
general anesthetic and hindlimb shaving), sham, or peripheral nerve
injury (PNI) surgery groups. Before surgery, all animals received acet-
aminophen (1 mg) and were subsequently anesthetized with gaseous
isoflurane (2.5% in O2). An1 cm incision was made in the upper left
hind leg. For PNI, the sciatic nerve was constricted with polyethylene
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tubing (PE20 for mice and PE90 for rats, 2 mm length for both species).
Animals in the sham group received a similar surgery but without nerve
ligation. The pain-naive control group received equivalent time under
isoflurane anesthesia, hindlimb shaving and all pharmaceutical treat-
ments but did not undergo skin incision.
Complete Freund’s adjuvant inflammatory pain model. Mice were
briefly anesthetized with 1–2% isoflurane (v/v) and 30 l of undiluted
complete Freund’s adjuvant (CFA; Sigma-Aldrich) was injected into the
intraplantar surface of the left hindpaw. Control animals received an
equivalent volume of intraplantar sterile saline.
AAV injection. Isoflurane-anesthetized mice were mounted on a ste-
reotaxic alignment system. A small incision was made to expose the skull
surface and to visualize bregma. Two holes were drilled in the skull over-
lying the ventral tegmental area (VTA). A 35-gauge bevel-tipped Hamil-
ton syringe was lowered bilaterally from the surface of the skull into the
VTA and virus was injected (0.3 l/side at 0.1 l/min). Viruses were
injected bilaterally using coordinates from bregma; AP:3.2, ML:0.7,
DV: 4.6. The needle was left in place for 5–7 min before being slowly
removed. The incision was closed with 5-0 silk sutures and animals re-
cover for at least 3 weeks to allow adequate time for viral expression
before conducting sham or peripheral nerve injuries. The TH-iCre-
AAV2/10 was synthesized by and obtained fromDr. Caroline Bass (Uni-
versity of Buffalo) and was recently shown to be effective in knocking
down KORs (Illiano et al., 2017). The AAV2/10 virus is highly neu-
rotrophic, is easily titrated, and has previously been used by various
groups to drive high levels of expression in both extremely small and
large brain regions of both rats and mice.
KOR agonist-stimulated GTPS autoradiography. Brains were col-
lected from naive, sham, and PNI mice 2 weeks postsurgery. Brains were
snap-frozen with isopentane at30°C and stored at80°C until further
processing. On day of processing, brains were sectioned coronally using a
cryostat (20-m-thick sections) at20°C. Sections were thaw-mounted
on Superfrost charged slides. Sections were pre-incubated in assay buffer
(50mMTris-HCl, 3mMMgCl2, 0.2mMEGTA, 100mMNaCl, 2mMGDP,
1 M DPCPX, pH 7.4) for 15 min. Agonist-stimulated KOR activity was
determined by incubating brain sections in [35S]GTPS (40 pM) with
U69,593 (10 M) for 1 h at RT. After incubation, slides were washed two
times in ice-cold wash buffer (50 mm Tris-HCl, pH 7.4) followed by a
brief wash in ice-cold deionized water (30 s). Slides were air-dried and
exposed to Kodak Biomax film together with [ 14C] standards for 2 d.
Films were developed using a Kodak GBXDeveloper and RapidFix solu-
tion. Films were digitally analyzed and binding quantified using aMicro-
Computer Image Device (MCID) normalized to a [ 14C] standard curve
in dpm/mg (MCID, Imaging Research). Data from the resulting agonist-
stimulated samples were compared with non-agonist-treated brain sam-
ples to determine the percentage activation of KOR above basal.
Western immunoblotting for KOR-P antibody specificity. Brains were
collected from naive WT or KOR KO mice 1 h after treatment with
vehicle or KOR agonist (U50, 488 1–30mg/kg, i.p.) and snap-frozenwith
isopentane at50°C and stored at80°C until sectioning. Brains were
sectioned coronally using a cryostat (150-m-thick section) at 20°C.
Sections were mounted on Superfrost charged slides, and tissue punches
(1 mm diameter) were taken using a disposable biopsy plunger to isolate
nucleus accumbens (NAc) tissue. Tissue punches were homogenized in
lysis buffer (50 mM Tris-base, 4 mM EDTA, pH 7.4) with protease inhib-
itor cocktail (Pierce Biotech; ThermoFisher Scientific). Samples were
then centrifuged at 10,000 g to remove DNA/debris, and supernatant
protein was extracted and stored at20°C. Protein samples were mixed
with NuPAGE LDS Loading Buffer and reducing reagent (Novex),
heated to 70°C for 10 min, and stored at 20°C for gel electrophoresis.
Gel electrophoresis of protein samples was conducted using an Invitro-
gen SDS-PAGE gel box, NuPAGE MES Running Buffer, and Bis-Tris
Mini Gels (Novex). Samples were loaded alongside PAGE-Ruler Plus
Prestained Protein Ladders (Fisher Scientific) and bands were separated
at 120 V for 2 h.
Proteins from gels were transferred to nitrocellulose (0.45 m pore
size; Novex) using a Bio-Rad protein transfer box at 4°C and 250 mA for
50 min. Membranes were blocked with 5% nonfat dried reconstituted
milk and TBS-T (1%) at RT for 1 h. Membranes were subsequently
incubated with phosphor-KOR antibodies produced in-house (Bruchas
laboratory, University of Washington, Seattle) at 1:1000 dilution in an-
tibody buffer (2% BSA, 2% gelatin from cold-water fish, TBS-T) over-
night at 4°C with gentle shaking. After primary antibody incubation,
membranes were washed 3 times with TBS-T (10 min per wash). Mem-
branes were then incubated with GOXCHHRP-conjugated anti-chicken
secondary antibodies (Novex) at 1:4000 dilution in 5% milk and TBS-T
(1%) for 90min at RTwith gentle shaking. Themembranes were washed
again three times with TBS-T (10 min per wash), followed by 1 min
revelation of membranes using GE Healthcare ECL-Plus substrate (GE
Healthcare). The membranes were visualized using a Li-Cor Odyssey Fc
Imager. Membranes were then washed and antibody-stripped using gly-
cine stripping buffer (200mM glycine, pH 2.6) with shaking at RT for 1 h,
then washed three times with TBS-T (10 min per wash). Membranes
were re-probed with -actin antibody (Abcam) at 1:4000 dilution over-
night and 4°C and subsequent anti-rabbit HRP-conjugated secondary
antibody (Life Technologies) at 1:4000 dilution for 1 h. Band intensities
were quantified using Li-Cor Image software and normalized to -actin
control bands.
Western immunoblotting of phosphorylated KOR. Brains were collected
from sham and PNI mice 2 weeks postsurgery and snap-frozen with
isopentane at 50°C and stored in 80°C until ready to be sectioned.
Brains were coronal-sectioned via cryostat (150 m thick) at 20°C,
mounted on Superfrost charged slides, and tissue punches (1 mm diam-
eter) were taken using a disposable biopsy plunger for medial prefrontal
cortex (mPFC), NAc, bed nucleus stria terminalis (BNST), amygdala
(AMYG), hippocampus (HIPP), thalamus (THAL), VTA, and dorsal
raphe nucleus (DRN). Tissue punches were homogenized in lysis buffer
(50 mM Tris-Base, 4 mM EDTA, pH 7.4) with protease inhibitor cocktail
(Pierce Biotech; ThermoFisher Scientific), centrifuged at 10,000  g to
remove DNA/debris, and supernatant protein was extracted and stored
at20°C. Protein samples were mixed with NuPAGE LDS Loading Buf-
fer and reducing reagent (Novex), heated to 70°C for 10 min, and stored
at20°C to be used for gel electrophoresis. Gel electrophoresis of protein
samples was conducted using Invitrogen SDS-PAGE gel box, NuPAGE
MES Running Buffer and Bis-Tris Mini Gels (Novex), and loaded along-
side PAGE-Ruler Plus Prestained Protein Ladder (Fisher Scientific), run
at 120 V for 2 h. Proteins from gels were transferred onto nitrocellulose
(0.45 m pore size; Novex) using Bio-Rad protein transfer box at 4°C
and 250 mA for 50 min. Membranes were blocked with 5% milk and
TBS-T (1%) at RT for 1 h.Membranes were subsequently incubatedwith
pKOR antibodies made in-house (Bruchas laboratory,Washington Uni-
versity, St. Louis) at 1:1000 dilution in antibody buffer (2% BSA, 2%
gelatin from cold-water fish, TBS-T) overnight at 4°C with gentle shak-
ing. After primary antibody incubation, membranes were washed 3
with TBS-T (10 min per wash) and GOXCH HRP-conjugated anti-
chicken secondary antibodies (Novex) were then incubated at 1:4000
dilution in 5%milk and TBS-T (1%) for 90 min at RT with gentle shak-
ing. The membranes were washed again 3 with TBS-T (10 min per
wash), followed by 1 min revelation of membranes using GE Healthcare
ECL-Plus substrate (GE Healthcare). The membranes were visualized
with Li-Cor Odyssey Fc Imager. Membranes were then washed and
antibody-stripped using glycine stripping buffer (200 mM glycine, pH
2.6) with shaking at RT for 1 h, then washed 3with TBS-T (10 min per
wash). Membranes were re-probed with -actin antibody (Abcam) with
1:4000 dilution overnight at 4°C, and subsequent anti-rabbit HRP-
conjugated secondary antibody (Life Technologies) with 1:4000 dilution
for 1 h. Band intensities were quantified using Li-Cor Image software and
normalized to beta-actin control bands.
Real-time quantitative PCR. Brains were collected from sham and PNI
mice 8 weeks postsurgery and were coronal-sectioned via cryostat (150
m thick) at 20°C and mounted on Superfrost charged slides (Fisher
Scientific). Tissue punches (1 mm diameter) were taken using a dispos-
able biopsy plunger (Miltex) for mPFC, NAc, BNST, AMYG, HIPP,
THAL, VTA, and DRN. Total RNA was collected from the brain tissue
punches via Trizol extractionmethod (Ambion Life Technologies). RNA
was converted to cDNAusing 100UofM-MulVReverse Transcriptase, 1
M Oligo d(T)23VN, and 2 mM dNTP mix (New England Biolabs), an-
nealed at 70°C and inactivated at 95°C. Real-time qPCR was conducted
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using primer sets for dynorphin (DYN), KOR, and-actin control genes.
Using, 96-well optical plates (Applied Biosystems), cDNA and PerfeCTa
SYBR Green FastMix containing the primer sets (Quanta Biosciences)
were loaded and run on ABI ViiA7 fast block qPCR machine using cycling
conditions in the PerfeCTa SYBR Green FastMix manual. Cycle threshold
outputs were calculated and normalized to the actin housekeeping gene to
compute CT. Relative expression levels were determined by normalizing
sham and neuropathic groups to three age-matched naive (non-surgery)
mice brain samples viaCTmethod.
RNAscope multiplex fluorescent in situ hybridization. Brains were col-
lected from pain-naive, sham, and PNI mice 2 weeks postsurgery. Brains
were perfused with 4% paraformaldehyde in saline and snap-frozen with
isopentane at 30°C and stored in 80°C until further processing.
Brains were coronal-sectioned via cryostat (18 m thick) at20°C, and
thaw-mounted on Superfrost charged slides. Custom fluorescent probe
labels were designed to fit complementary sequences on mRNA strands
for  opioid receptor gene (Oprk1) carrying fluorescent AlexaFluor 488,
tyrosine hydroxylase (TH ) or pro-enkephalin (Penk) carrying Atto555,
and glutamate decarboxylase 1 (Gad1) or pro-dynorphin (Pdyn) carry-
ing Atto647. Brain slices were incubated with 4% paraformaldehyde and
then dehydrated with 50, 70, and 100% ethanol washes for 5 min each.
Slides were then incubated overnight at 20°C in 100% ethanol. Slides
were then taken out and dried for 5 min and a hydrophobic barrier was
drawn around the brain slices. Probes were activated in oven at 40°C for
10min. Slides were then incubated with probes following the RNAScope
Multiplex processing kit (ACDBiosciences). Slides were then cover-
slipped and sealed with nail polish and stored in dark at 20°C until
visualization. Slides were visualized using a Nikon Ti-E wide-field in-
Figure 1. Enhanced KOR mediated place aversion in chronic pain animals. a, Timeline for CPA to KOR agonist (U50,488) in control (naive and sham surgery) and PNI mice. b, In female mice,
U50,488 (U50, 1–10mg/kg, i.p.) did not produce a place aversion in pain-naive, sham, and PNI. A one-way ANOVA of U50,488 dose revealed no significant effect at any dose (1 mg dose: F(2,23)
0.216, p 0.808, 5mgdose: F(2,37) 1.296, p 0.286, 10mgdose: F(2,22) 0.003 p 0.997). One-sample t test for difference froma theoretical value of zero (no preference) revealed that none
of the dose tested produced a place aversion independent of surgery (1 mg dose in naive: t 0.468, p 0.643, sham: t 0.542, p 0.602, PNI: t 0.465, p 0.655; 5 mg dose in naive t
0.767, p 0.468, sham: t 1.733, p 0.103, PNI: t 1.78, p 0.094; 10 mg dose in naive: t 1.578, p 0.153, sham: t 1.268, p 0.252, PNI: t 0.974, p 0.358). c, In male mice,
U50,488 (1–10 mg/kg, i.p.) dose-dependently produced place aversion in pain-naive and shammale mice, but unlike female mice, all doses produced place aversion in male chronic pain mice. A
one-way ANOVA of U50,488 dose revealed a significant effect at 1 and 5 mg doses in PNI mice (1 mg dose: F(2,24) 9.102, p 0.0011, 5 mg dose: F(2,37) 26.19, p 0.0001, 10 mg dose:
F(2,22) 0.465 p 0.634). One-sample t test for difference from a theoretical value of zero (no preference) revealed that all doses produced a place aversion in PNI mice (1 mg dose in naive: t
0.021, p 0.984, sham: t 2.301, p 0.0504, PNI: t 4.426, p 0.0022; 5 mg dose in naive t 2.823, p 0.0166, sham: t 10.83, p 0.0001, PNI: t 19.66, p 0.0001; 10 mg dose
in naive: t 3.14, p 0.0164, sham: t 2.528, p 0.0353, PNI: t 2.531, p 0.0392). d, Dose–response curves for female mice. A two-way ANOVA revealed no significant effect of surgery
(F(2,82) 0.558, p 0.572), dose (F(2,82) 1.743, p 0.181), or interaction (F(4,82) 0.227, p 0.852). e, Dose–response curves formalemice. A two-way ANOVA revealed a significant effect
of surgery (F(2,85) 6.707, p 0.002) and an interaction (F(4,85) 4.746, p 0.0017), but not dose (F(2,85) 2.392, p 0.0976). For all datasets, #compares to sham and *compares to naive.
Data are expressed as mean	 SEM. N 7–16 per group. f, Heat map of representative data male U50,488 (U50) 5mg/kg dose.
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verted fluorescence microscope and NIS Elements software setup. Image
fluorescence intensities were quantified using FIJI (ImageJ) software.
Microdialysis probe insertion. Fast microdialysis to detect extracellular
dopamine levels was performed essentially as previously described (Yang
et al., 2013, 2015). At zeitgeber time (ZT)10–ZT12, each subject was
briefly (1–3 min) anesthetized using isoflurane for insertion of a CMA/7
microdialysis probe (1 mm) into a guide cannula (AP:1.5, ML:0.8,
DV:3.5). Immediately after insertion, regular artificial CSF (aCSF; 147
mM NaCl (Fluka, 73575), 3.5 mM KCl (Fluka, 05257), 1.0 mM CaCl2
(Aldrich, 499609), 1.0 mM NaH2PO4, 2.5 mM NaHCO3 (Fluka, 88208),
1.2 mMMgCl2 (Sigma-Aldrich, 449172), pH 7.3	 0.03 at room temper-
ature) was continuously perfused through the probe at 2 l/min for
30–60 min followed by a 0.3 l/min flow rate for an additional 12–14 h
to allow recovery from probe insertion.
Morphine-induced dopamine overflow. For all mice, at ZT1–ZT2 the
day after probe insertion, the aCSF flow rate through the probes was
increased to 2l/min for 60–120min before collecting dialysate samples
for analysis. The dialysate sampling rate was 5min/sample. Basal samples
were collected for 60min and each animal’s average baseline level used to
calculate percentage evoked release as the mean of the sample values
between 30 and 45 min (3 values) following the beginning of sampling.
At the end of the 60 min basal sampling period, mice received an intra-
peritoneal injection of 10 mg/kg morphine. Morphine-induced dopa-
mine overflow was sampled for an additional 250 min. The KOR
antagonist JDTic (10mg/kg, i.p.) was administered 24 h beforemorphine
injection.
HPLC. Analysis was performed using an Eicom integrated high-
performance liquid chromatography (HPLC) system (HTEC-500, Ei-
com) with an Insight autosampler and two Eicom EAS-20s online
autoinjectors. Chromatographic separation was achieved using an Ei-
compak PP-ODS II stationary phase (4.6 mm, i.d.  30 mm, 2 m,
particle diameter) and a phosphate buffered mobile phase with 96 mM
NaH2PO4 (Fluka, 17844), 3.8 mM Na2HPO4 (Fluka, 71633), pH 5.4,
1.8–2.5% MeOH (EMD, MX0475–1), 50 mg/L EDTA.Na2 (Fluka,
03682), and 500 mg/L sodium decanesulfonate (TCI, I0348) in water
purified via a Milli-Q Synthesis A10 system (EMD Millipore). The col-
umn temperature was maintained at 20–21°C. The volumetric flow rate
was 350–500l/min. Electrochemical detection was performed using an
Eicom WE-3G graphite working electrode with an applied potential of
450 mV versus a Ag/AgCl reference electrode. Dopamine (Sigma-
Aldrich, H8502) standards were prepared in aCSF. Standard curves,
which were verified daily, encompassed physiological dopamine concen-
tration ranges (0, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, 1000 nM using 20l
sample volumes). The limit of detection was 60 amol and the prac-
tical limit of quantification was 120 amol using a 20 l sample
volume. All dialysate samples for in vivo experiments were collected at
5 min intervals at a dialysate flow rate of 2 l/min using EAS-20s
autoinjectors. Samples were injected immediately onto the HPLC
system in an online configuration.
Drug-induced conditioned place preference/aversion. This test was con-
ducted using an unbiased, counter-balanced three chamber apparatus as
previously described (Cahill et al., 2013; Taylor et al., 2015a). Each box
(28 28 19 cm) was divided into two equal-sized conditioning cham-
bers separated by a neutral compartment. The two chambers were dis-
tinguished with visual and tactile cues.Mice were placed in the apparatus
and allowed free access to both chambers. The time spent in each cham-
ber was recorded using an infrared CCD camera attached to a computer
Figure 2. Dose-dependent KOR-mediated hypolocomotion. a, Timeline for KOR-agonist-induced hypolocomotion. b, c, The presence of chronic pain enhanced U50-induced hypolocomotion in
bothmale and femalemice at the 5mg/kg dose (middle). A two-way ANOVA in femalemice (for the 5mg dose) demonstrated a significant effect of surgery F(2,35) 16.62, p 0.0001, treatment
F(1,35) 26.99, p 0.0001 and an interaction F(2,35) 4.231, p 0.0226. A two-way ANOVA inmalemice (for the 5mgdose) demonstrated a significant effect of treatment F(1,43) 20.36, p
0.0001, but no effect of surgery F(2,43) 2.956, p 0.063 and no interaction F(2,43) 1.783, p 0.1804. Data are expressed asmean/ SEM. N 4–8 per group. d, U50,488 (1–10mg/kg
i.p.) produced a dose-dependent effect on locomotor activity in female andmalemice. For femalemice, a two-way ANOVA revealed a significant effect of surgery F(2,52) 12.72, p 0.0001, dose
F(2,52) 39.54, p 0.0001and an interaction F(4,52) 2.62, p 0.045. For male mice, a two-way ANOVA revealed a significant effect of dose F(2,50) 45.36, p 0.0001 and interaction
F(4,50) 2.82, p 0.0345, but not dose F(2,50) 0.048, p 0.9528. For all datasets, *compares saline to U50,488 treatment. e, Representative activity tracks of U50,488 (5mg/kg, i.p.) -induced
locomotion in male mice.
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running behavioral tracking software (Noldus, EthoVision). Mice were
conditioned to drug over 6 or 8 d (half vehicle and half drug) counter-
balanced for chamber and order of drug injection. Post-conditioningwas
performed without treatment (day following conditioning), in which
animals were again allowed to explore the whole box freely for 15 or 30
min. Time spent and activity in each compartment were recorded during
the sessions. Preference scores were calculated using the following for-
mula: [Time in Test(paired)  Time in Test(unpaired)]  [Time at
baseline(paired) time at baseline(unpaired)].
Single chamber place conditioning. Single chamber conditioning was
used to assess ongoing pain in two models of chronic pain. This test was
conducted using an unbiased, counter-balanced three chamber appara-
tus. Each box (28  28  19 cm) was divided into two equal-sized
conditioning chambers separated by a neutral compartment. The two
chambers were distinguished with visual and tactile cues. Mice were
placed in the apparatus and allowed free access to both chambers. The
time spent in each chamber was recorded using an infrared CCD camera
attached to a computer running behavioral tracking software (Noldus,
EthoVision). Mice received an injection of saline daily and were imme-
diately returned to their home cage or placed in one of the conditioning
chambers for 30 min. Mice were counterbalanced to chamber and order
of home cage versus conditioning chamber. Post-conditioning was per-
formed the day following conditioning, inwhich animals were allowed to
freely explore the entire apparatus for 30 min. Time spent and activity in
each compartment were recorded during the
sessions and the time (15–30 min depending
on the experiment) in each compartment was
used for calculating preference scores. Pref-
erence scores were calculated using the fol-
lowing formula: [Time in Test(paired)Time
in Test(unpaired)]  [Time at baseline-
(paired)  time at baseline(unpaired)]. For
PNImice, conditioningwas commenced either
7 or 14 d following nerve injury, whereas for
inflammatory pain, testing commenced 3 d fol-
lowing induction of inflammation.
Locomotor activity. Locomotor activity was
measured in an open-field apparatus. The ap-
paratus consisted of a Plexiglas box arena (28
cm2 and 19 cm high) with an open top. The
distance traveled and velocity were recorded
using an infrared CCD camera attached to a
computer running behavioral tracking soft-
ware (Noldus, EthoVision). Mice were habitu-
ated to test boxes for 3 d before surgery to
induce neuropathic pain or control surgery.
One hour before surgery, mice received an in-
jection of vehicle or the KOR antagonist JDTic
(10mg/kg, i.p.). On Day 6 and/or Day 11 post-
surgery, animals received an injection of vehi-
cle or the KOR agonist U50,488 (1, 5, or 10
mg/kg, i.p.) and were placed immediately in
the apparatus for 20 min to test the ability
of JDTic to block KOR agonist-induced
hypolocomotion.
Intra-VTA DAMGO and conditioned place
preference. Male Long–Evans rats were anes-
thetized with isoflurane andmounted on a ste-
reotaxic frame to allow implantation of a
bilateral intra-VTA cannulae (CMA; coordi-
nates from bregma: AP:5.4, ML:0.75, DV:
8.0). Rats were used instead ofmice to ensure
accurate targeting of drug to the VTA.We have
demonstrated comparable systemic opioid
place preference responses between rats and
mice in control and chronic pain models
(Cahill et al., 2013). Animals were individually
housed and allowed to recover for 7 d after
intra-VTA cannula insertion, at which point
the animals received a sham or peripheral
nerve injury. Seven days after nerve injury, place conditioning was per-
formed as described above. The apparatus consisted of two large com-
partments of equal size (45 45 30 cm) joined by a gray tunnel (18
18 30 cm). Chambers were distinguished with textual and visual cues.
Groups were assigned so that any innate bias to side was balanced be-
tween treatment groups, as described above. During the conditioning
sessions, animals received four trials with [D-Ala2, N-MePhe4, Gly-ol]-
enkephalin (DAMGO; 1 ng/0.5 l/side infused at a rate of 0.25 l/min)
and four trials with sterile saline, injected directly into the VTA, andwere
confined to the chambers for 30 min. On the post-conditioning day,
animals were allowed free access to both chambers in a drug-free state.
The time spent in the drug-paired chamber was measured over 30 min.
Light/dark test. The apparatus consisted of light and dark sides (25
cm3) separated by a guillotine door. The lit compartment was brightly
illuminated (1000 lux).Mice were placed in the dark compartment at the
beginning of the test, and the time spent in the lit compartment was
recorded over 5 min. Activity and location was tracked by Noldus Etho-
Vision software.
Forced swim test. The apparatus for this test was a tank (20 cm diame-
ter  35 cm high) filled with water to 15 cm for males, and 10 cm for
females. Water temperature was maintained at 28°C. This test evaluates
depressive-like behavior in terms of the total time mice spend immobile
when forced to swim in an inescapable water tank (Porsolt et al., 1977). A
Figure 3. Chronic pain enhances recovery of KOR-mediated effects after JDTic. a, Timeline for KOR agonist-induced hypoloco-
motion at either 6 or 11 d post-KOR antagonist administration (JDTic 10 mg/kg, i.p.). All mice were injected with the KOR
antagonist JDTic (10 mg/kg, i.p.) 24 h before surgery. b, KOR blockade prevented KOR agonist U50,488 (U50 10 mg/kg, i.p.)
-induced hypolocomotion in naive, sham, and PNI femalemice at 6 d following KOR antagonist administration. A two-way ANOVA
in female mice on Day 6 demonstrated no significant effect of surgery F(2,42) 0.3691, p 0.6936, or treatment F(1,42) 1.57,
p 0.2172 and no interaction F(2,42) 2.471, p 0.0967. Thus, at 6 d post-JDTic administration, KOR agonist-induced hypolo-
comotion was blocked in female mice independent of the presence of chronic pain. c, In contrast, the KOR antagonist prevented
U50-induced hypolocomotion in naive and sham but not PNI male mice. A two-way ANOVA in male mice on Day 6 demonstrated
no significant effect of surgery F(2,62) 0.128, p 0.8801, or treatment F(1,61) 2.417, p 0.1243 but therewas an interaction
F(2,62) 6.856, p 0.0020. Thus, JDTic blocked KOR agonist-induced hypolocomotion in naive and sham male mice but not
chronic pain male mice. At Day 11, JDTic continued to block U50,488-induced effects in both male and female naive mice, but did
not prevent hypolocomotion of the KOR agonist in either sham or PNI female or male mice. A two-way ANOVA in female mice on
Day 11demonstrated a significant effect of surgery F(2,42)058.11,p0.0001 andan interaction F(2,42)5.42,p0.0081but
no effect of treatment F(1,42) 1.754, p 0.1856. A two-way ANOVA inmalemice on Day 11 demonstrated no significant effect
of surgery F(2,57) 2.816, p 0.0682 or interaction F(2,57) 2.629, p 0.0809, but an effect of treatment F(1,57) 36.67, p
0.0001. Data are expressed asmedianwith 25 and 75%quartiles,minimumandmaximumvalueswith all data points included for
N 7–12 per group. *Compares saline to U50 within a surgery group.
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mouse was considered to be immobile once swimming and escape be-
haviors have ceased, and it floated belly-down with its head above the
water. The test session lasted 6min but only the last 4min of the test were
scored. Water in the tank was replaced with clean, 28°C water following
each trial. Videos were recorded for all mice and subsequently scored by
two independent observers blind to experimental condition.
Experimental design and statistical analyses. Data are either expressed
either as scatter plots for raw data and bar graphs for mean	 SEM or as
medians with 25 and 75% quartiles with minimum and maximum data
points. Data are analyzed by either GraphPad Prism v7.0 or PAWS Sta-
tistics 18 (SPSS). All behavioral data were shown to fit assumptions of a
general linear model and data were subjected to factorial ANOVAs. To
Figure4. KORupregulation and functionwithin the nucleus accumbens of chronic pain animals.a, Inmulticolor images,Oprk1 (white), Pdyn (green), and pro-enkephalin (pink) gene expression
wasdetectedwithRNAscopemultiplex florescent in situhybridization in theNAcof pain-naive, shamandPNImice. Scale bar, 25m.b, In thePNImodel of neuropathic pain, the expressionofOprk1
transcript was increased in male, but not female mice compared with pain naive and sham controls. Tissue was collected 2 weeks post-induction of pain by PNI. One-way ANOVAs revealed a
significant effect in male (F(2,12) 19.26, p 0.001), but not female (F(2,18) 3.483, p 0.054) PNI mice. *Compares naive to PNI, # compares sham to PNI. In contrast, Pdyn transcript was
increased in bothmale and female PNImice. One-way ANOVAs revealed a significant effect inmale (F(2,12) 10.83, p 0.01) and female (F(2,17) 3.511) PNImice comparedwith pain-naive but
not sham control mice. *Compares naive to PNI. Data are expressed as mean	 SEM. N 12 per group. c, Representative autoradiograms and quantification of KOR agonist-induced [35S]GTPs
binding in coronal brain sections fromnaive, shamandPNImalemice. Increases in KORagonist (U69,593) stimulated [35S]GTPs bindingare evident in theNAcof PNImalemice comparedwithboth
pain-naive and sham controls. Increases in binding were evident in both the core (*compares to naive, and # compares to sham, one-way ANOVA, F(2,21) 5.455, p 0.0124) as well as the shell
(*compares to naive, # compares to sham, one-way ANOVA, F(2,21) 5.988, p 0.0088) of the NAc. d, Representative autoradiograms and quantification of KOR agonist-induced [
35S]GTPs
binding in coronal brain sections from naive, sham and PNI female mice. No differences in KOR agonist (U69,593) stimulated [35S]GTPs binding are evident between pain-naive, sham and PNI
femalemice in either the NAc core (one-way ANOVA, F(2,21) 0.1296, p 0.8972) or NAc shell (one-way ANOVA, F(2,21) 0.1669, p 0.8474). Data are expressed asmean	 SEM forN 8 per
surgical group. For all data presented, tissue was collected 2 weeks post-induction of pain by PNI.
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determine sex differences, we conducted three-way ANOVAs, with sur-
gery and sex as between animal factors and time as the within animal
factor. For conditioned place preference data, the amount of time (s)
spent in the drug-paired and vehicle-paired compartments on the post-
conditioning test day is presented, as well as the preference score. To
determine the presence of place aversion induced by ongoing pain, we
also performed a one-sample t test to determine whether means were
significantly different versus a hypothetical value of 0 (where 0 is no
preference). A two-way ANOVA with drug dose and group as the
between-subject factors was used to examine differences in the magni-
tude of preference or aversion across neuropathic pain, sham, and naive
groups. Two-way ANOVAs were also used to determine the effects of the
KOR antagonist on locomotor activity, time spent in the light compart-
ment in the light dark test, or time spent immobile in the forced swim
test, and differences in extracellular dopamine concentrations. Either
Tukey’s or Sidak post hoc analysis was used to correct for multiple
comparisons.
Results
Chronic pain induces changes in KOR-mediated place
aversion and hypolocomotion
To investigate the behavioral/affective relationship betweenKOR
systems and chronic pain states, we used the conditioned place
preference(CPP)/conditioned place aversion (CPA) paradigm to
test for preference or aversion to the KOR agonist U50,488 (1–10
mg/kg, i.p.; Fig. 1a) in mice with peripheral nerve injury (PNI).
Post-conditioning testing in a drug-free state revealed that
U50,488 produced a dose-dependent place aversion in male but
not female pain-naive mice (Fig. 1b–e). At a dose that did not
produce place aversion in pain-naive or sham surgical control
mice, U50,488 (1 mg/kg, i.p.) produced place aversion in male
PNI mice (Fig. 1c,e). None of the doses of U50,488 produced a
significant place aversion in female mice regardless of the pres-
ence of chronic pain. Examples of heat maps of KOR-mediated
place aversion are shown in Figure 1f.
We also investigated KOR-mediated activity effects and po-
tential enhancement in chronic pain states. The KOR agonist
U50,488 produced a dose-dependent decrease in distance trav-
eled in male mice compared with saline for all groups tested (Fig.
2d). In femalemice, the lowest dose of U50,488 (1mg/kg) did not
induce hypolocomotion in either of the surgical groups (Fig. 2b),
whereas there was a significant effect of this dose in pain-naive
but not shamor PNImalemice (Fig. 2c). At the intermediate dose
of 5mg/kg, U50,488 produced hypolocomotion in bothmale and
female PNI groups, but not the pain-naive groups. At the highest
dose of U50,488 (10 mg/kg), hypolocomotion was evident in all
surgical groups for both sexes. Interestingly, the intermediate
dose (5mg/kg) produced a significant effect inmale shambut not
female shammice. Examples of hypolocomotion activity traces to
the 5 mg dose are shown in Figure 2e.
To further examine the effects of chronic pain on KOR-
mediated effects, we took advantage of the long-lasting KOR an-
tagonist effects of JDTic, which can last up to 2 weeks following a
single injection (Deehan et al., 2012). Resensitization of KOR-
induced behaviors requires synthesis of newKOR protein to pro-
duce subsequent KOR-induced effects. We reasoned that if there
was an increase in KOR activation in chronic pain states that
KORs may turn over faster and predicted that the duration of
effects produced by JDTicwould be shorter in chronic pain states.
Here, JDTic (or vehicle) was injected 24 h before sham or PNI
surgery (Fig. 3). At 6 or 11 d postsurgery, mice were injected with
the KOR agonist U50,488 (10 mg/kg, i.p.) or saline and locomo-
tor activity was determined.
As hypothesized, KOR agonist-induced hypolocomotion
(U50,488 10 mg/kg, i.p.) was blocked at 6 d following JDTic
administration in both male and female pain-naive and sham
mice (Fig. 3), confirming the long-lasting blocking effects of
JDTic. Similarly, KOR agonist-induced hypolocomotion was
blocked at 6 d post-JDTic injection in female pain mice (Fig. 3b).
However, JDTic failed to blockU50,488 hypolocomotion inmale
PNI mice (Fig. 3c). At 11 d post-JDTic injection, U50,488-
induced hypolocomotion was evident in both males and female
sham and PNI mice, but not in pain-naive mice. Thus, the KOR
agonist-induced hypolocomotion recovers faster after KOR an-
tagonist treatment in male, but not female PNI animals com-
pared with surgical controls. Together, these data demonstrate
that KORbehavioral sensitivity and turnover is increased in chronic
neuropathic pain states, particularly in male mice. This increased
function of the KOR system is consistent with evidence that KOR-
induced hypolocomotion (Heidbreder et al., 1993; Karper et al.,
2000), aversion (Van’t Veer et al., 2013) and reduced dopamine
release in the ventral striatum (Leitl et al., 2014a) are criticallymedi-
ated by regulation of dopaminergic circuitry.
Chronic pain-induced changes in  opioid system expression
and function in the nucleus accumbens
To determine the extent to which chronic pain alters expression
and function of KORs and expression of the KOR endogenous
ligand DYN in the mesolimbic circuitry, we performed ex vivo
analysis of mRNA expression using RNAscope multiplex in situ
hybridization and KOR G-protein coupling via GTPS autora-
diography. We observed a profound increase in KOR (Oprk1)
mRNA expression (Fig. 4a,b), where KOR mRNA expression in
Table 1. Quantification of Oprk1 gene expression in brain regions of 8 week
postsurgery sham and chronic painmice
Sham 2 ddCT Sham SEM PNI 2 ddCT PNI SEM
Male
NAC-ipsi 52.09 2.97 170.54* 3.00
NAC-con 260.3 4.16 359.54* 3.88
VTA-ipsi 50.63 5.85 156.49* 4.73
VTA-con 76.17 4.90 173.29* 4.94
Female
NAC-ipsi 2.258 0.38 1.353 0.45
NAC-con 3.739 0.41 3.610 0.40
VTA-ipsi 0.49 0.433 0.08 0.401
VTA-con 0.09 0.363 0.65 0.397
Brain regions are also subcategorized by hemispheres in terms of ipsilateral (ipsi) and contralateral (contra) to PNI.
Statistical significance is denoted with asterisk where p 0.05. A total of 10 sham and 10 PNI mice were used in
these experiments.
Table 2. Quantification of Pdyn gene expression in brain regions of 8 week
postsurgery sham and PNI mice
Sham 2 ddCT Sham SEM PNI 2 ddCT PNI SEM
Male
NAC-ipsi 0.379 1.244 4.690 1.371
NAC-con 1.042 1.521 10.89* 1.418
VTA-ipsi 0.286 1.134 1.755 1.410
VTA-con 2.215 1.093 5.535 1.454
Female
NAC-ipsi 6.751 1.898 33.5 15.23
NAC-con 0.069 0.006 6.19* 0.432
VTA-ipsi 0.18 0.029 5.633** 1.455
VTA-con 0.34 0.025 7.488*** 0.0959
Brain regions are also subcategorized by hemispheres in terms of ipsilateral (ipsi) and contralateral (contra) to PNI.
Statistical significance is denoted with asterisk where p 0.05. A total of 10 sham and 10 PNI mice were used in
these experiments.
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the contralateral NAc was increased in
male, but not female PNI mice compared
with pain-naive and sham control mice.
This increase in KORmRNA remained el-
evated for at least 8 weeks post-PNI as de-
termined by quantitative real-time PCR
(Table 1). Pdyn mRNA was significantly
increased in the contralateral (right)NAc of
both male and female mice at both 2 weeks
(Fig. 4a,b) and 8 weeks (Table 2) post-PNI.
Similar sex differences were evident in KOR
activation as measured by GTPS autora-
diography. Activation of KORs, quantified
byGTPS autoradiography in theNAc core
and shell 2 weeks post-PNIwas increased in
male (Fig. 4c) but not female PNImice (Fig.
4d) comparedwithpain-naiveor shamcon-
trol groups. Examples of heatmap autora-
diogramsof [35S]GTPSbinding are shown
inFigure4, candd,wherewarm(red) colors
reflect more agonist-stimulated KOR activ-
ity and cold (blue) colors indicate less KOR
activity.
To provide further evidence that
chronic pain upregulates endogenous
KOR system activity, we determined
changes in expression of the phosphory-
lated state of KORs (in the absence of ex-
ogenous agonist), as a measure of tonic
KOR activation in the PNI pain state. Using a phospho-specific
KOR (KOR-P) antibody, we determined KOR-P levels in various
brain regions usingWestern blotting techniques. Antibody spec-
ificity was confirmed by showing a dose-dependent increase in
KOR agonist-stimulated KOR-P expression in the NAc of pain-
naive animals (Fig. 5a) and by the absence of signal inmembranes
prepared fromKORKOmalemice (Fig. 5b). The phosphorylated
state of KORs was increased in the contralateral NAc of PNImale
mice (Fig. 5c). There was also an increase in phosphorylatedKOR
in the contralateral NAc of sham mice, which we believe likely
reflect effects because of postoperative pain. Together, these data
show that chronic pain associated with PNI increases the expres-
sion and function of the KORs in theNAc ofmale, but not female
mice.
KOR regulation of mesolimbic dopamine and reward in
chronic pain states
Kappa opioid receptors are known to modulate mesolimbic do-
paminergic circuitry by inhibiting dopamine release at dopami-
nergic nerve terminals within the NAc (Spanagel et al., 1992;
Ebner et al., 2010; Cahill et al., 2014b; Ehrich et al., 2015; Chartoff
et al., 2016). Preclinical and human subject research have identi-
fied strong correlations between dysfunction of this mesolimbic
circuitry and chronic pain (Taylor et al., 2016). Our prior studies
have shown that opioid-evoked dopamine release is disrupted in
amodel of neuropathic pain (Taylor et al., 2014, 2015a). Using in
vivo microdialysis in awake, freely-moving mice, we asked
whether blockingKORswould recover the loss of opioid-induced
dopamine release in the NAc. No significant differences in basal
dopamine levels between pain and control animals were observed
(Table 3). Consistent with our previous findings, systemic ad-
ministration of morphine did not evoke dopamine release above
basal levels inmale PNImice (Fig. 6c). However, when thesemice
were pretreated with JDTic, morphine-induced dopamine re-
lease recovered to levels similar to the sham group. This finding is
concordant with prior reports of blocking KOR recovered 
opioid-evoked dopamine release in a model of inflammatory
(formalin) pain (Narita et al., 2005).
Seeking pain relief is a motivational state that engages cir-
cuitry involved in affect and salience (Navratilova and Porreca,
2014; Borsook et al., 2016; Taylor et al., 2016). The mesolimbic
circuitry plays a central role in motivational processes and incor-
porates dopaminergic neurons in the VTA that project to the
NAc (Berridge and Kringelbach, 2013, 2015; Zarrindast and
Khakpai, 2015). Next, we asked whether KOR blockade restores
opioid reward in a CPP paradigm, as hypodopaminergic states
contribute to chronic pain (Borsook et al., 2016; Taylor et al.,
2016) and mood disorders (Elman et al., 2013). The rewarding
effects of intra-VTA injection of the -opioid agonist DAMGO
were determined to isolate reward expression to the mesolimbic
dopaminergic circuitry.
We and others previously showed that intra-VTA  opioid
injection is sufficient to produce a CPP (McBride et al., 1999;
Narita et al., 2010), but this preference is blunted in chronic
Figure 5. Chronic pain increases the phosphorylated state of the KOR. a, Characterization of KOR-P antibody. Systemic admin-
istration of the KOR agonist U50,488 (U50) dose-dependently increased the phosphorylated state of the receptor (KOR-P) in the
NAc of naive mice. b, The molecular species identified by the KOR-P antibody was absent in homogenates of brains from KOR
KO/mice. N 4–6 per group. c, In the absence of exogenously administered KOR agonist, the “activated” state of the KOR
(phosphorylated) was significantly increased in the contralateral (contra) NAc of male PNI and sham animals when normalized to
pain-naive tissue. Tissue was collected 2 weeks post-induction of pain by PNI. *Compares to ipsilateral (ipsi) sham (t 2.249) or
PNI (t 2.139). Data are expressed as mean	 SEM for N 4–10 per group.
Table 3. Basal dopamine levels in the NAc as detected by in vivomicrodialysis
Sham PNI PNI JDTic
0.20938 0.02728 0.10100
0.22982 0.12125 0.21516
0.12838 0.05175 0.48927
0.12442 1.32625 0.79104
0.65862 0.31025 0.47336
0.08182 — 0.23101
— — 0.63812
Mice underwent sham or PNI to induce neuropathic pain 14 d prior to assessing basal dopamine levels by in vivo
microdialysis. JDTic was administered 24 h prior to conducting microdialysis measurements. Each data point is a
mean of eight measurements taken consecutively in 5 min samples. Data are raw data values. N 5–7 per group.
One-way ANOVA showed no difference between groups: F(2,15) 0.4558, p 0.642.
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neuropathic pain states (Narita et al., 2005). Male rats were con-
ditioned to intra-VTA DAMGO beginning 7 d post-nerve injury
(Fig. 6a), a time pointwhenmechanical allodynia is robust. JDTic
administration had no effect on opioid reward in sham animals
(Fig. 6b). Consistent with our previous data (Taylor et al., 2015a),
intra-VTADAMGOdid not elicit a CPP in chronic pain animals.
Remarkably, JDTic treatment in neuropathic pain animals re-
stored DAMGO-induced CPP (Fig. 6b). Together, these results
demonstrate that KORs contribute to the loss of opioid-evoked
dopamine release and reward-related behaviors in chronic neu-
ropathic pain.
Chronic pain induced changes in  opioid system expression
and function in the ventral tegmental area
KORs are located presynaptically on dopamine neurons in the
NAc as well as postsynaptically within the NAc. Because KOR
inhibition by JDTic recovered morphine-evoked dopamine re-
lease in male PNI mice (Fig. 6c) we determined whether pain-
induced changes in the KOR system were evident in dopamine
cell bodies projecting from the VTA to the NAc. Fluorescent in
situ hybridization enabled identification of KORmRNA (Oprk1)
expression in various cell types via colabeling of heterogeneous
populations of GABAergic and dopaminergic neurons within the
VTA (Fig. 7a,b) of shamandPNImale and femalemice at 2weeks
following induction of the pain state. We found that Oprk1
mRNA levels were increased in PNI male and female mice com-
pared with sham: Oprk1 levels were primarily localized to TH
(dopamine)-containing neurons, but not glutamic acid decar-
boxylase (GAD1, GABA) neurons. Using, quantitative real-
time PCR, we determined that increases in KOR mRNA were
sustained for at least 8 weeks post-PNI in male, but not female
PNI mice (Table 1). Sex differences were also evident in the
GTPS autoradiography functional assay, where KOR agonist-
stimulated [35S]GTPS binding was increased in the VTA of
male, but not female PNI mice compared with sham controls
(Fig. 7c,d). The mechanisms responsible for the upregulation of
the KOR system within mesolimbic circuitry of chronic pain re-
main unclear; however, these data demonstrate that chronic neu-
Figure 6. KOR regulates opioid-induced reward and dopamine release. a, Time course for drug treatment and conditioningwith intra-VTA DAMGO. b, CPP of intra-VTA opioid agonist DAMGO
(1 ng/bilateral injection) in sham and PNI mice. Intra-VTA DAMGO produced a CPP in sham but not PNI mice. Pretreatment of mice with KOR antagonist JDTic (10 mg/kg, i.p.) did not alter DAMGO
CPP in sham animals but recovered DAMGO CPP in pain animals. Data are expressed mean	 SEM. N 8–9 per group. Two-way ANOVA revealed a significant effect of surgical group (F(1,29)
5.184, p 0.05), treatment (F(1,29) 7.483, p 0.05) and a significant interaction (F(1,29) 4.233, p 0.05). *p 0.05 compares sham to PNI in vehicle-treatedmice. Images depict cannula
placement for DAMGO delivery. c, Morphine (10 mg/kg, i.p.) failed to stimulate extracellular dopamine in PNI male mice, but treatment with KOR antagonists JDTic (10 mg/kg, i.p.) restored
morphine-evoked extracellular dopamine levels. Microdialysis experiments were conducted 2 weeks post-induction of pain by PNI. A two-way ANOVA revealed a significant effect of time
(F(51,627) 2.364, p 0.0001) and surgery (F(2,627) 76.56, p 0.0001) but no interaction (F(102,627) 0.994, p 0.513. Images depict location of microdialysis fiber location.
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ropathic pain causes a sex-dependent increase inKOR expression
and function.
Negative reinforcement is driven by KOR blockade
Although KOR blockade recovered mesolimbic dopamine levels
and opioid reward in chronic pain states, it was important to
directly assess whether KOR contributes to the tonic-aversive
component of chronic pain. The long-acting properties of the
KOR antagonist JDTic prevent it from being used in a CPP par-
adigm because of the requirement of learning drug effects with
contextual cues. We thus, decided to use the nonselective opioid
antagonist naloxone (Codd et al., 1995) in pre-pro-enkephalin
KOmice. Naloxone produces a CPA inWTmice (Dymshitz and
Lieblich, 1987) but this aversion is driven by endogenous en-
kephalin, where the CPA is absent in PENK KO mice (Shoblock
and Maidment, 2007). Using this transgenic mouse with ge-
netic loss of enkephalin, we therefore asked whether naloxone
would produce a CPP via naloxone’s ability to block KORs.
Thus, naloxone via KOR blockade may produce expression of
negative reinforcement by removing the tonic aversive state of
pain. This approach was chosen as available short acting KOR
antagonists did not prevent KOR-induced hypolocomotion in
our pilot studies.
Consistent with previous findings, naloxone produced a CPA
in pain-naive WT mice that was absent in the PENK KO mice
(Fig. 8b). Naloxone also produced aCPA in chronic pain PNIWT
mice. However, naloxone elicited a place preference in chronic
pain PENK KO mice (Fig. 8b). To determine whether the CPP
produced by naloxone was because of antagonism of KORs, we
pretreated mice with the KOR antagonist JDTic before condi-
tioning with naloxone. Because expression of a CPP is dependent
upon the learned association of drug effects with contextual cues,
the acute KOR blocking effects of naloxone would be prevented
by pretreatment with the long-acting KOR antagonist JDTic. In
this experiment, JDTic prevented naloxone-induced CPP in PNI
PENK KO mice but had no effect on naloxone CPA in WT ani-
mals (Fig. 8c). These data suggest that the naloxone-induced CPP
in chronic pain PENK KOmice was associated with KOR block-
ade by naloxone. These findings further contribute to the idea
that KORs contribute to the ongoing tonic aversive nature of
chronic pain.
To provide further evidence that KORs contributed to the
tonic-aversive component of chronic pain, we used two addi-
tional approaches. Previous research reported that analgesic
treatment via a peripheral nerve block or systemic administration
of analgesics drugs prevents the expression ofmorphine-induced
CPP (negative reinforcement) in chronic pain animals because of
the absence of motivation to seek pain relief (Navratilova et al.,
2015). Here, we showed that JDTic effectively blocked expression
of CPP produced by systemic administration of morphine in
chronic pain, but not sham animals (Fig. 8e). Thus, alleviation of
the tonic-aversive component of chronic pain by KOR blockade
was sufficient to prevent expression ofmorphine CPP in pain but
not sham animals. We suggest that this outcome results from the
Figure 7. KOR expression and function is increased in themidbrain of chronic pain animals.Oprk1 gene expression (white) was detectedwith RNAscopemultiplex florescent in situ hybridization
in both GABA (green; identifiedwith GAD) and TH (red,male; pink, female) positive neurons in the VTA of female (a) andmale (b) mice. The PNImodel of neuropathic pain increased the expression
of Oprk1mRNA in the VTA of pain male and female compared with sham surgical controls. Data are expressed as mean	 SEM for N 6–8 per surgical condition. Male: two-way ANOVA reveled
a significant effect of gene (F(2,30) 9.539, p 0.001), but not surgery (F(1,30) 1.33, p 0.258). There was also a significant interaction (F(2,30) 9.33, p 0.001). Female: two-way ANOVA
reveleda significant effect of gene (F(2,90)59.37,p0.001), and surgery (F(1,90)5.52,p0.05)butnot an interaction (F(2,90)1.933,p0.1507). *Compares shamtoPNI. c, Representative
autoradiograms and quantification of KOR agonist-induced [35S]GTPs binding in coronal brain sections from naive, sham, and PNI male and female mice. d, Increases in KOR agonist U69593-
stimulated [35S]GTPs binding are evident in the VTA of male, but not female PNI mice. *Compares to naive and sham. Data are expressed as mean	 SEM for N 8 per surgical group.
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primary motivation for morphine CPP being associated with re-
lief from the tonic-aversive component of pain.
KORmediates a sex-dependent tonic aversive component of
chronic pain
Next, we took advantage of a conditioning paradigm where ani-
mals were conditioned to only one chamber of the CPP appara-
tus. Male and female PNI, but not sham, mice showed a CPA to
the conditioning chamber, demonstrating the ongoing tonic-
aversive component of pain can be captured using this protocol
(Fig. 9a,b). In separate cohorts of mice, administration of JDTic
24 h before the beginning of conditioning prevented place aver-
sion in male, but not female PNI mice (Fig. 9a). To test the
generalizability of KOR contributions to the ongoing tonic-
aversive component of pain in other models, we performed sim-
ilar experiments in male mice injected with CFA to induce
chronic inflammatory pain. Using this model, CFA also pro-
duced a place aversion that was blocked by JDTic (Fig. 9b). It is
noteworthy that KOR inhibition had no effect on mechanical
withdrawal thresholds in sham or chronic pain male or female
mice (Fig. 9c). These findings further implicate KOR involve-
ment in pain circuitry is restricted to the affective but not sensory
dimension of chronic pain.
We examined the circuitry involved in the tonic-aversive
component of pain using KOR conditional KO (cKO) mice.
Here, AAV-TH-cre or control virus (AAV-eGFP) was injected
into the VTA of KOR cKOmice. As an additional control, AAV-
TH-cre was injected into WT C57BL/6 mice 3 weeks before in-
Figure 8. The tonic-aversive component of chronic pain is driven by opioid receptor activation. a, Time Course of drug treatment and conditioning. b, In naivemice: naloxone (NLX) produced
a CPA inWTmice, but not in PENK KOmice. In amodel of chronic neuropathic pain induced by PNI, naloxone produced a CPA inWTmice, but produced a CPP in PENK KOmice. Heatmaps of naloxone
CPA or CPP are from representative data. Two-way ANOVA revealed a significant effect of genotype (F(1,35) 113.2, p 0.001), treatment (F(1,35) 23.39, p 0.001), but not interaction
(F(1,35) 0.0295, p 0.864). *Compares genotype within PNI groups and compares genotype in surgery control mice or between control and PNI in the PENK KO groups. c, In PENK KO mice,
administration of the KOR antagonist JDTic (10 mg/kg, i.p.) prevented naloxone CPP in chronic pain animals. Two-way ANOVA revealed a significant effect of surgery (F(1,37) 4.826, p 0.05),
treatment (F(1,37)3.795,p0.05), anda significant interaction (F(1,37)5.325,p0.05). *Compares saline-treated control andPNIgroupsor salineand JDTic treatments inPNIgroups. InPENK
WT littermate mice, administration of the KOR antagonist JDTic (10 mg/kg, i.p.) had no effect on naloxone CPA in surgical control or chronic pain animals. Two-way ANOVA revealed no significant
effect of surgery (F(1,32) 0.1763, p 0.677) or treatment (F(1,32) 0.6015, p 0.443). However, all groups showed a significant effect comparedwith a theoretical value of 0 demonstrating all
groups demonstrated a CPA to naloxone (t 5.52–10.88, **p 0.01 to ***p 0.001). Data are expressed as medians with 25 and 75% quartiles, minimum andmaximum values with all data
points included; N 5–18 per group. d, Time course of treatment and conditioning paradigm. e, Systemic administration of morphine produced a CPP in sham mice that was not altered by
pretreatment with the KOR antagonist JDTic (10 mg/kg, i.p.); however, place preference to morphine was blocked by JDTic in chronic pain mice. Two-way ANOVA revealed a significant effect of
surgery (F(1,30) 4.955, p 0.05) and treatment (F(1,30) 8.579, p 0.01), but not an interaction (F(1,30) 2.985, p 0.0943). *Compares saline to JDTic in PNI and JDTic shamandPNI groups.
Data are expressed as median with 25 and 75% quartiles, minimum and maximum values with all data points included; N 8–10 per group.
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ducing chronic neuropathic pain followed by single chamber
conditioning. The RNAscope technique confirmed elimination
of KORs fromTH dopaminergic neurons in KOR cKO, but not
WT mice (Fig. 10). The PNI-induced place aversion was present
in WT mice injected with TH-cre-virus as well as in KOR cKO
mice injected with control virus. However, place aversion was
absent inKORcKOmicewhereKORexpressionwas significantly
reduced within VTA TH neurons (Fig. 10). Together, these
results provide strong evidence that KORs in dopaminergic me-
solimbic circuits contribute to the tonic-aversive component of
chronic pain.
KOR antagonists attenuate negative affect in chronic pain
states but is not sex dependent
The findings described above suggest sex differences in the in-
volvement of KORs in the affective dimension of pain.We there-
fore determined whether similar sex differences were evident in
other measures of affect. Others have reported anti-depressant-
like and anti-anxiety-like effects of KOR antagonists in rodent
models of affective-like behavior (Crowley and Kash, 2015). The
PNI model of chronic pain induces both anxiogenic and depres-
sive phenotypes in mice (Yalcin et al., 2011). The administration
of JDTic increased percentage time in the light compartment of
the light/dark test (Fig. 11a) anddecreased immobility time in the
forced-swim test (Fig. 11b) in PNI male and female mice, dem-
onstrating that inhibition of KORs improves anxiety-like and
affective-like deficits in behavior of chronic pain animals. None-
theless, we did not observe sex-dependent effects in these tests.
Thus, there is a divergence in mechanisms underlying the ongo-
ing tonic-aversive component of pain compared with other mea-
sures of affect often precipitated by pain.
Figure 9. Sex-dependent KOR involvement in the ongoing tonic-aversive component of chronic pain. a, Time course and treatment regimen of single chamber conditioning to capture place
aversion of sham and chronic pain (PNI) mice. Mice received saline (i.p.) injections daily in their home cage or in one conditioning chamber. Sham animals conditioned to the CPP apparatus did not
showplace aversion or preference to the chamberwhere they received saline but PNImale and femalemice developed an aversion to the conditioning chamber. This aversion demonstrates ongoing
tonic aversive component of chronic pain. Treatingmale, but not femalemicewith the KOR antagonist JDTic (10mg/kg, i.p.) prevented aversion to the conditioning chamber.Male: two-wayANOVA
revealed a significant effect of treatment (F(1,28) 9.923, p 0.01), an interaction (F(1,28) 4.781, p 0.05), and an effect of surgery (F(1,28) 3.581, p 0.05). *p 0.05 compares
saline-treated control and PNI groups as well as control surgery and PNI in vehicle-treated groups. Female: two-way ANOVA revealed a significant effect of surgery (F(1,28) 8.346, p 0.01), but
no interaction (F(1,28) 0.150, p 0.701) or treatment effect (F(1,28) 0.241, p 0.627). *Compares saline-treated control and PNI groups as well as control surgery and PNI in vehicle-treated
groups. Data are expressed as median with 25 and 75% quartiles, minimum and maximum values with all data points included; N 8 per group. b, Time course and treatment regimen of
conditioning to capture place aversion after CFA. Sham animals conditioned to CPP apparatus did not show place aversion or preference to chamber that they received saline but CFA male mice
developed an aversion to the conditioning chamber. Treatingmicewith KOR antagonist JDTic (10mg/kg, i.p.) prevented this aversive state. Two-way ANOVA revealed a significant effect of surgery
(F(1,28) 5.281, p 0.05) and treatment (F(1,28) 12.76, p 0.01), but no interaction (F(1,28) 2.192, p 1.499). *Compares saline-treated control and PNI groups. Data are expressed as
median with 25 and 75% quartiles, minimum andmaximum values with all data points included; N 8 per group. c, Mechanical withdrawal thresholds determined at 2 weeks postsurgery were
significantly lower in PNI comparedwith shammice. Administration of JDTic (10mg/kg, i.p.) 24 h before testing did not alter withdrawal thresholds in PNI or shammice. Two-way ANOVA revealed
a significant effect of surgery (F(1,28) 111.5, p 0.001), but not drug treatment (F(1,28) 0.356, p 0.556), and there was no significant interaction (F(1,28) 0.167, p 0.686). Data are
expressed as median with 25 and 75% quartiles, minimum and maximum values with all data points included; N 8 per group.
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Discussion
The present study provides evidence that chronic pain increases
KOR expression and function within the mesolimbic circuitry
that contributes to a tonic-aversive component of pain in a sex-
dependent manner. We have previously shown that KOR
agonist-induced anti-nociception in male, but not female mice,
was mediated by engagement of stress pathways, as analgesia was
blocked by anxiolytics (Taylor et al., 2015b). Sex differences in
KOR function have been reported in human and animal studies.
Indeed, PET studies in humans show that KOR binding is greater
in men than women in multiple brain regions, including areas
associated with pain affect such as the anterior cingulate cortex
(Vijay et al., 2016).Differences between sexes can occur as a result
of hormonal differences, either during development or in adult-
hood, or as a result of genetic differences due to the complement
of genes expressed on the X or Y chromosomes. Because the type
of gonadal hormones is closely tied to the complement of sex
chromosomes (XX vs XY), it has been difficult to separate the
effects of each of these variables. However, both hormones and
sex chromosomes have been implicated in
KOR-mediated sex differences. For exam-
ple, the sex-dependent differences in sensi-
tivity to the depressive effects of KOR
agonists in a model of intracranial self-
stimulation was independent of estrous cy-
cle state in females or gonadectomy inmales
(Russell et al., 2014). In contrast, KOR-
mediated anti-nociception was enhanced
by hormone treatment (Dawson-Basoa
and Gintzler, 1996) and the sex-specific
effects of KOR-mediated anti-nociception in
male but not female mice was shown to be
mediated by estrous phase (Abraham et al.,
2018).
Considerable evidence suggests that
the KOR system within the NAc underlies
negative affective states and heightens
stress reactivity in various psychiatric dis-
orders. For example, DYN expression is
increased in the ventral striatum of sui-
cidal individuals and in animal models of
depression (Hurd et al., 1997; Peckys and
Hurd, 2001). Similarly, the aversive effects
produced by KOR agonists are partially
mediated by their role in the NAc, where
they modulate dopamine transmission
from the VTA (Van’t Veer et al., 2013).
However, no prior study has shown the
tonic-aversive component of chronic pain
is mediated by KORs. Our study demon-
strates that KOR modulation of dopa-
mine release underlies the tonic aversive
component of pain, but it unclear
whether thismodulation is because of reg-
ulation of dopamine release within the
NAc or other projection sites. We previ-
ously demonstrated that intra-VTA opi-
oid reward and evoked dopamine release
within the NAc are blunted in chronic
pain states (Taylor et al., 2015a). Here we
show that the blunted release and reward
are recovered by KOR antagonists, how-
ever the source of DYN responsible for
KOR activation within the NAc remains unclear. We show that
Pdyn mRNA is increased in the NAc of chronic pain mice sug-
gesting a likely source is DYN-expressing medium spiny neurons
(Al-Hasani et al., 2015). However, DYN regulation of dopamine
may occur via another system; it was recently hypothesized that
another DYN source may be orexin neurons projecting from the
lateral hypothalamus (Tejeda and Bonci, 2019). It is important to
note that KOR activation does not contribute to aversion to an
acute pain stimulus. Neither administration of a KOR agonist or
antagonist prevented visceral pain (acetic acid)-induced place
aversion (Bagdas et al., 2016). Additionally, acute inflammatory
or visceral pain was reported to reduce dopamine release in the
NAc and to depress intracranial self-stimulation (Leitl et al.,
2014a,b). However, neither effect was reversed by pretreatment
with a KOR antagonist. We propose that the KOR system may
only be engaged following tissue or nerve injury that induces a
prolonged or chronic, but not acute pain states.
The possibility exists that the ability of KOR inhibition to
recover dopamine release and opioid rewardmay increase risk of
Figure 10. Deleting KOR frommesolimbic dopamine prevents an ongoing pain aversive state. Time course of conditioning and
AAV-TH-cre treatment in KOR cKO or C57BL/6 mice. Elimination of KOR from VTA TH neurons prevented place aversion in male
PNImice. t(12) 3.46, *p 0.05. Data are expressed asmedianwith 25 and 75%quartiles, minimumandmaximum valueswith
all data points included for N 4–8 per group. Bottom, Represented images demonstrate the absence of KORmRNA in the VTA
of TH-cre/KOR loxP but not control mouse groups.
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opioid misuse and addiction. Although a
complex issue, KOR antagonism or ab-
sence of KORs increases drug-induced
dopamine release (Chefer et al., 2005;
Doyon et al., 2006), as well as increases
nicotine, methamphetamine or ethanol
reward as determined by conditioned
place preference and self-administration
studies (Matsuzawa et al., 1999; Mitchell
et al., 2005; Whitfield et al., 2015). Never-
theless, KOR antagonists are being devel-
oped for the treatment of addiction
because of their ability to block stress and
cue-induced relapse, where the rationale
for such treatment is driven in part by the
ability of KOR antagonists to block stress-
related pathways (Crowley and Kash,
2015; Chavkin and Koob, 2016).
It is not clear whether restoring dopa-
mine release and dopamine-dependent
reward would increase addiction poten-
tial in chronic pain states, as reward is not
solely dependent on dopamine. More im-
portantly, opioid use for pain treatment is
associated with negative reinforcement
rather than increasing hedonic tone. For
example, rodents in chronic pain that un-
dergo pain treatment with gabapentin or
other analgesics do not show place prefer-
ence for morphine (Navratilova et al.,
2015). In clinical studies, opioid misuse
and addiction was shown to be lower in
chronic pain patients than the general
population receiving opioids, if suscepti-
ble individuals (comorbid mood disorder
or psychopathology, genetic susceptibility
or previous substance misuse) were sepa-
rated from the cohort (Fishbain et al.,
2008). Because hypo-dopaminergic tone
in chronic pain impairs motivated behav-
ior and likely contributes to the occur-
rence of psychopathology commonly
comorbid with chronic pain (Carroll and Carlezon, 2013; Taylor
et al., 2015b, 2016), the ability of KOR antagonists to restore
dopamine signaling may represent a novel approach to manage
affective dimensions of chronic pain. This mechanism may un-
derlie the effectiveness of buprenorphine (a partial  opioid ag-
onist with KOR antagonist properties) in alleviating chronic pain
and improving quality of life (Uberall and Mu¨ller-Schwefe,
2013), andmay also explain why buprenorphine when combined
with naloxone for treatment of opioid addiction in chronic pain
patients also decreased subjective pain (Worley et al., 2015).
Conclusions
We have discovered in two animal models of chronic pain that
the expression and function of KOR systems are increased in
mesolimbic brain structures. Whereas the affective and sensory
components of pain are mediated by overlapping circuitry, lim-
bic structures includingmesolimbic circuitry are engaged to pro-
cess the emotional component of pain. Considerable evidence
suggests that the  opioid systems within the NAc underlies neg-
ative affective states and heightens stress reactivity in various psy-
chiatric disorders. Here we show that  opioid receptors are
sufficient to drive the tonic-aversive component of chronic pain;
this emotional component of pain is argued to significantly
impact patients’ quality of life (compared with the sensory
component).
These findings represent a significant contribution to under-
standing mechanisms of chronic pain because there is consider-
able research interest in validating peripherally restricted 
agonists as a novel analgesics, whereas our data suggest that 
blockade might prove effective. A case in point is that opioids
remain one of our most effective pharmacotherapeutic agents in
treating pain, which is likely because of their ability to blunt both
the sensory and emotional components of pain. In fact, many
patients indicate they still feel pain when taking opioids but the
pain no longer bothers them. Thus, novel analgesic treatments
must focus on alleviating the emotional component of pain if we
are ever to replace opioids for treating long-term pain. The im-
pact of the present study is also broadly relevant to affective dis-
orders associated with disruption of reward circuitry and thus,
likely contributes to many of the devastating sequelae of chronic
pain, including the poor response to treatment of come patients,
debilitating affective disorders and substance abuse. Because
Figure 11. No sex-dependent effect of KOR antagonists to block pain-induced affective like behavior. a, JDTic (10 mg/kg, i.p.)
significantly increased the percentage time in the light compartment of the light dark anxiety-like affective-like test of bothmale
and female PNImice.Male: two-wayANOVA reveals a significant effect of surgery (F(1,76) 9.997, p 0.0023) and an interaction
(F(1,76) 5.747, p 0.0190), but not of treatment (F(1,76) 0.0513, p 0.8214). Female: two-way ANOVA reveals a significant
effect of surgery (F(1,44) 6.787, p 0.0125) and an interaction (F(1,44) 10.08, p 0.0027), but not of treatment (F(1,44)
1.663, p 0.2040). Data are expressed as raw data and mean	 SEM for N 10–24 per group. Male: #compares sham to PNI
JDTic treatment, female: *compares sham to PNI saline-treated mice, $compares PNI saline to PNI JDTic treatment. b, JDTic (10
mg/kg, i.p.) significantly decreased the immobility time in the forced swim depressive-like affective-like test of male and female
PNI mice. Male: two-way ANOVA reveals a significant effect of surgery (F(1,72) 9.077, p 0.0036) and treatment (F(1,72)
23.57,p0001), and an interaction (F(1,72)4.659,p0.0125). Female: two-wayANOVA reveals a significant effect of surgery
(F(1,44) 8.147, p 0.0066) and treatment (F(1,44) 14.4, p 0.0004), but not an interaction (F(1,44) 0.867, p 0.3569).
Data are expressedas rawdataandmean	SEMforN10–24pergroup.Male: *comparesPNI tonaive, #compares shamtoPNI,
$compares to PNI saline to PNI JDTic-treated mice. Female: #compares sham to PNI JDTic-treated mice.
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KORs are upregulated in areas of the CNS involved inmood, our
findings likely bear on other disorders, including anxiety disor-
ders and depression that demonstrate high comorbidity with
chronic pain. Moreover, KORs are known to be involved in
stress-induced relapse of drugs of abuse. Therefore, KOR antag-
onists may reduce prescription opioid misuse in pain patient
populations.
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